期刊文献+

非布司他在中国健康人体内药动学和药效学 被引量:10

Pharmacokinetics and pharmacodynamics of febuxostat under fasting conditions in healthy Chinese subjects
原文传递
导出
摘要 目的:研究国产非布司他在中国健康受试者体内药动学和药效学特点。方法:36名健康受试者随机分组,分别接受单剂量空腹口服非布司他片40,80,120 mg和多剂量空腹口服非布司他片80 mg,给药前后不同时间取血测定血药浓度、血清尿酸水平(UA)。采用HPLC-MS-MS法测定受试者血浆样品中非布司他的浓度。UA为临床检验所得。结果:(1)非布司他在40~120 mg剂量范围内,呈线性药动学特征;连续给药在健康受试者体内不存在蓄积。(2)单次空腹口服40,80,120 mg非布司他后,结果表明给药剂量与UA24呈线性特征;对3个剂量组UA24/Dose进行方差分析,表明各剂量组间有显著性差异(P<0.05)。(3)连续给药(80 mg,qd×7 d)后第3天UA下降了38.13%,第7天下降达52.69%,第4~7天稳定在低值状态(145.2±10.3)(mol·L-1,与给药前1天基础值(UA-1)相比,连续给药7 d平均降低(51.8±7.0)%。结论:健康受试者空腹口服国产非布司他片,以UA为临床药效指标,通过降低血尿酸水平而呈现出药理活性。单次给药在40,80和120 mg组间UA降低显示明显的剂量依赖性。连续给药3 d即可产生显著的降尿酸作用,给药7 d平均降低(51.8±7.0)%。健康受试者UA在停药后48 h恢复至正常值范围。 OBJECTIVE To study the pharmacokinetic and pharmacodynamic characteristics of domestic febuxostat after single oral dose and multiple oral doses under fasting conditions in healthy Chinese subjects.METHODS Thirty-six healthy subjects were randomized to receive febuxostat by single oral dose(40,80,120 mg)and multiple oral doses(80 mg,qd×7 d)under fasting conditions.At a series of time points before or after administration,the blood samples were collected,the plasma drug levels and serum uric acid(UA) were determined by HPLC-MS-MS mothod and clinical laboratory test,respectively.RESULTS During the dosage of 40-120 mg of febuxostat it showed a linear pharmacokinetic character.Drug accumulation was not detected after multiple oral doses.When febuxostat was administered at a single dose of 40 mg,80 mg and120 mg,UA24 was linearly corrected to the dosage.The relationship between effect UA24 and the three single doses(40,80 mg and120 mg)was analzed with ANOVA.The difference between every single dose was significant(P0.05).After three day,the percentage decrease in serum uric acid(UA0-24h)was 38.13%.After seven day,the percentage decrease in serum uric acid(UA0-24h)was 52.69%.Mean percentage decrease was 51.83%±7.0% within seven days.CONCLUSION Domestic febuxostat can be decrease the level of serum uric acid,and the decrease of UA is linear corresponding to dosage.Mean percentage decrease was 51.83%±7.0% within seven days.The clinic indexes of UA returned to normal range after drug discontinuance in healthy subjects.
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2013年第12期942-945,共4页 Chinese Journal of Hospital Pharmacy
关键词 非布司他 药动学 药效学学 血尿酸(UA) febuxostat pharmacokinetics pharmacodynamics serum uric acid
  • 相关文献

参考文献5

  • 1韩莹,朱翊,傅得兴.非布司他治疗高尿酸血症伴痛风的药理与临床评价[J].中国新药与临床杂志,2010,29(8):635-638. 被引量:30
  • 2国家食品药品监督管理局.药品临床试验质量管理规范[s].2003.
  • 3国家食品药品监督管理局.化学药物临床药代动力学研究技术指导原则[S].2005:15-25.
  • 4Khosravan R, Grabowski B, Wu JT, et al. Effect of food and antacid on the pharmacokinetics and pharmacodynamics of fe- buxostat[J]. Brit J Clin Pharmaco,2007,65(3 ):355-363.
  • 5亚瑟.J.阿特金森,等著,魏伟,等译,临床药理学原理[M].2版,北京:科学出版社,2007.

二级参考文献7

  • 1CHOI HK, MOUNT DB, REGINATO AM. Pathogenesis of gout [J]. Ann Intern Med, 2005, 143(7): 499-516.
  • 2OKAMOTO K, EGER BT, NISHINO T, et al. An extremely potent inhibitor of xanthine oxidoreduetase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition[J]. J Biol Chem, 2003, 278(3) : 1848-1855.
  • 3SCHLESINGER N. Management of acute and chronic gouty arthritis: present state-of-the-art[J]. Drugs, 2004, 64 (21) : 2399- 2416.
  • 4HOSKISON KT, WORTMANN RL. Management of gout in older adults: barriers to optimal control[J]. Drugs Aging, 2007, 24 (1): 21-36.
  • 5Anon. ULORIC.[EB/OL]. [2009-02-13]. http: //www. accessdata. fda. gov/drugsatfdadocs/label/2009/0218561b1. pdf.
  • 6SCHUMACHER HR, BECKER MA, WORTMANN RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28- week, phase Ⅲ, randomized, double-blind, parallel-group trial [J]. Arthritis Rheum, 2008, 59(11 ) : 1540-1548.
  • 7SCHUMACHER HR Jr, BECKER MA, LLOYD E, et al. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study[J]. Rheumatology (Oxford), 2009, 48 (2) : 188-194.

共引文献34

同被引文献65

  • 1彭嘉,孙文东,张丽萍,陈艳,姬艳丽.肾气虚症、自由基与中医衰老理论[J].新疆医科大学学报,2004,27(6):641-642. 被引量:8
  • 2毛黎明,朱彩凤.慢性痛风性肾病中医辨治[J].浙江中医学院学报,2005,29(6):38-39. 被引量:12
  • 3陈军.清热化湿通络法治疗痛风性肾病35例[J].中华中医药杂志,2005,20(11):661-662. 被引量:8
  • 4朱深银,周远大,杜冠华.防治痛风药物的研究进展[J].医药导报,2006,25(8):803-806. 被引量:31
  • 5付桂香,李建民,周勇,赵世萍.山茱萸总苷抗炎免疫抑制作用及其机理的大鼠实验研究[J].中华微生物学和免疫学杂志,2007,27(4):316-320. 被引量:32
  • 6LI Y D, YAO C E, SHEN R J, et al. The clinical research progress of febuxostat-a selective xanthine oxidase inhibitor .中国药房, 2013, 24(26): 2472-2475.
  • 7WANG H D, DENG P, CHEN X Y, et al. Development and validation of a liquid chromatography-tandem mass spectrometry method for the determination of febuxostat in human plasma.Biomed Chromatogr, 2013, 27(1):34-38.
  • 8LUKRAM O, PARMAR S, HANDE A. Determination of febuxostat in human plasma using ultra-performance liquid chromatography tandem mass spectrometry. Drug Testing Analysis, 2013, 5(6): 492-499.
  • 9LIU X X, LIU R J, DING L, et al. Pharmacokinetics of febuxostat in healthy chinese volunteers. Arzneimittelforschung, 2012, 62(10): 463-469.
  • 10GRABOWSKI A B,KHOSRAVAN R,VERNILLET L,et al.Metabolism and excretion of[14C]febuxostat,a novel nonpurine selective inhibitor of Xanthine Oxidase,in healthy malesubjects[J].J Clin Pharmacol,2011,51:189-201.

引证文献10

二级引证文献64

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部